MML Investors Services
CRNX icon

MML Investors Services’s Crinetics Pharmaceuticals CRNX Stock Holding History

MML Investors Services’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$232K Buy
6,396
+1,002
+19% +$44.8K ﹤0.01% 2736
2025
Q4 		$251K Buy
+5,394
New +$240K ﹤0.01% 2745

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

MML Investors Services's CRNX Position: Q1 2026 in Review

MML Investors Services increased its Crinetics Pharmaceuticals (CRNX) stake by 19% in Q1 2026, buying an estimated $44.8K and bringing the position to 6,396 shares worth $232K. The position accounts for ﹤0.01% of the portfolio, ranked #2736.

MML Investors Services first reported a position in CRNX in Q4 2025 and has held it in 2 quarters since. The position peaked at $251K in Q4 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • MML Investors Services held 6,396 shares of Crinetics Pharmaceuticals worth $232K as of Q1 2026.
  • MML Investors Services bought 1,002 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $44.8K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of MML Investors Services's portfolio in Q1 2026, its #2736 holding.
  • MML Investors Services first reported a position in Crinetics Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • MML Investors Services's Crinetics Pharmaceuticals position peaked at $251K in Q4 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on MML Investors Services's 13F filing for Q1 2026, filed 4 May 2026.